This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Trial to Assess Chelation Therapy (TACT)

Sponsored by Mt. Sinai Medical Center, Miami

About this trial

Last updated 12 years ago

Study ID

654

Status

Completed

Type

Interventional

Phase

Phase 3

Placebo

No

Accepting

18-75 Years
50+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 13 years ago

What is this trial about?

The purpose of this study is to determine the safety and effectiveness of ethylene diamine tetra-acetic (EDTA) chelation therapy in individuals with coronary artery disease.

What are the Participation Requirements?

Inclusion Criteria for Participants:

- Heart attack at least 6 weeks prior to study start

Exclusion Criteria for Participants:

- Serum creatinie level greater than 2.0 mg/dL

- Platelet count less than 100,000/µL

- Blood pressure greater than 160/100

- Chelation therapy within 5 years prior to study start

- History of allergic reactions to EDTA or any of the therapy's components

- Coronary or carotid revascularization procedures within 6 months prior to study start
or a scheduled revascularization

- Cigarette smoking within 3 months prior to study start

- Childbearing potential

- History of liver disease

- Active heart failure or heart failure hospitalization within 6 months.

- Diagnoses of additional medical conditions that could otherwise limit patient survival

- Inability to tolerate 500-mL infusions weekly.

Locations

Location

Status